We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cell Signaling Survivin (71g4b7) Rabbit mAb (Pe Conjugate)
List Price
$454.50
Your Price
$454.50
Cell Signaling Survivin (71g4b7) Rabbit mAb (Pe Conjugate) - CSIG (Additional S&H or Hazmat Fees May Apply)
NETA PART:
CSIG-5875S
MFG.PART:
5875S
UNSPSC:
12352203
Manufacturer:
Cell Signaling
| Size | 100 µl (50 tests) |
| Reactivity | H M R |
| Sensitivity | Endogenous |
| Source/Isotype | Rabbit IgG |
| Application/Dilution | {Flow Cytometry (Fixed/Permeabilized): 1:50} |
| Storage | Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibodies. Protect from light. Do not freeze. |
| Specificity/Sensitivity | Survivin (71G4B7) Rabbit mAb (PE Conjugate) detects endogenous levels of total Survivin protein. |
| Species Reactivity | Human, Mouse, Rat |
| Source/Purification | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Cys60 of human Survivin protein. |
| Background | Survivin is a 16 kDa anti-apoptotic protein highly expressed during fetal development and cancer cell malignancy (1). Survivin binds and inhibits caspase-3, controlling the checkpoint in the G2/M-phase of the cell cycle by inhibiting apoptosis and promoting cell division (2,3). This regulatory process requires the phosphorylation of survivin at Thr34 by p34 cdc2 kinase (4). Gene targeting using a Thr34 phosphorylation-defective survivin mutant, as well as antisense survivin, have been shown to inhibit tumor growth (5,6). |
| SKU | CSIG-5875S |
|---|---|
| Featured | No |
| Supplier Part Number | 5875S |
| UM | EA |
| UNSPSC | 12352203 |
| Manufacturer Name | Cell Signaling |
| MSDS URL | Click here |
| Temperature | +4C |
| CountryOfOrigin | United States |
| ProductLine | CSIG |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 5 |
| Hazardous | N |
| ACT Ecolabel | No |